Eva Molina
University of Navarra
13 Papers
151 Citations
Eva Molina is an academic researcher from University of Navarra. The author has contributed to research in topics: Endothelial protein C receptor & VKORC1. The author has an hindex of 7, co-authored 13 publications.
Chat about Author
Papers
Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol
José Hermida,José Zarza,Ignacio Alberca,Ramón Montes,Marı́a Luz López,Eva Molina,Eduardo Rocha +6 more
TL;DR: Because acenocoumarol sensitivity with the 2C9*2 variant does not seem to be clinically relevant, the drug could be an alternative to warfarin in 2C 9*2 carriers.
97
Receptor of Activated Protein C Promotes Metastasis and Correlates with Clinical Outcome in Lung Adenocarcinoma
Iker Antón,Eva Molina,Diego Luis-Ravelo,Carolina Zandueta,Karmele Valencia,Cristina Ormazábal,Susana Martínez-Canarias,Naiara Perurena,Maria J. Pajares,Jackeline Agorreta,Luis M. Montuenga,Victor Segura,Ignacio I. Wistuba,Javier De Las Rivas,José Hermida,Fernando Lecanda +15 more
TL;DR: EPCR and its ligand APC promote cell survival that contributes to tumor cell endurance to stress favoring prometastatic activity of lung adenocarcinoma and is a novel target of relevance in the clinical outcome of early-stage lung cancer.
Is EPCR a multi-ligand receptor? Pros and cons.
TL;DR: A new image of EPCR is offered in the light of its extended panel of ligands, including Factor VII/VIIa and factor Xa, two other serine proteases that play a central role in haemostasis and are also involved in signalling processes influencing wound healing, tissue remodelling, inflammation or metastasis.
34
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk
Mikel Allende,Eva Molina,Elisabet Guruceaga,Ibai Tamayo,José Ramón González-Porras,Tomás José González-López,Estefanía Toledo,Obdulia Rabal,Ana Ugarte,Vanesa Roldán,José Rivera,Julen Oyarzabal,Ramón Montes,José Hermida +13 more
TL;DR: Hsp70 induction is a novel approach to delay thrombus formation with minimal bleeding risk, and is especially promising for treating AF patients and in other situations where there is also a major bleeding hazard.
The functional properties of a truncated form of endothelial cell protein C receptor generated by alternative splicing
TL;DR: It is demonstrated that a new, soluble form of endothelial cell protein C receptor generated by alternative splicing, in which the transmembrane region is replaced by a 56-residue tail (tEPCR), was detected in the endothelium and cancer cells.